Relationship of MMP-14 and TIMP-3 expression with macrophage activation and human atherosclerotic plaque vulnerability

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Johnson, Jason L ^a,b   Jenkins, Nicholas P ^a,b   Huang, Wei Chun ^b   Di Gregoli, Karina ^a,b   Sala Newby, Graciela B ^b   Scholtes, Vincent P W ^c   Moll, Frans L ^c   Pasterkamp, Gerard ^c   Newby, Andrew C ^b  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; CD68 ANTIGEN; CYCLOOXYGENASE 2; GAMMA INTERFERON; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; MATRIX METALLOPROTEINASE 14; MESSENGER RNA; MICRORNA 24; OXIDIZED LOW DENSITY LIPOPROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR RELA;

ARTICLE; BLOOD CLOTTING; CAROTID ATHEROSCLEROSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MACROPHAGE; MACROPHAGE ACTIVATION; MALE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ATHEROSCLEROTIC PLAQUE; CELL CULTURE; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

MUS; ORYCTOLAGUS CUNICULUS;

CELLS, CULTURED; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGE ACTIVATION; MACROPHAGES; MATRIX METALLOPROTEINASE 14; PLAQUE, ATHEROSCLEROTIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 84925874469     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/276457     Document Type: Article

References (40)

1. R. Virmani, A. P. Burke, A. Farb, and F. D. Kolodgie, "Pathology of the vulnerable plaque," Journal of the American College of Cardiology, vol. 47, no. 8, pp. C13-C18, 2006.
2. A. C. Newby, "Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture," Physiological Reviews, vol. 85, no. 1, pp. 1-31, 2005.
3. C. M. Dollery and P. Libby, "Atherosclerosis and proteinase activation," Cardiovascular Research, vol. 69, no. 3, pp. 625-635, 2006.
4. A. C. Newby, "Matrix metalloproteinase inhibition therapy for vascular diseases.," Vascular pharmacology, vol. 56, no. 5-6, pp. 232-244, 2012.
5. F. Schneider, G. K. Sukhova, M. Aikawa et al., "Matrix metalloproteinase-14 deficiency in bone marrow-derived cells promotes collagenaccumulation inmouse atherosclerotic plaques," Circulation, vol. 117, no. 7, pp. 931-939, 2008.
6. V.Casagrande, R.Menghini, S.Menini et al., "Overexpression of tissue inhibitor of metalloproteinase 3 in macrophages reduces atherosclerosis in low-density lipoprotein receptor knockout mice,"Arteriosclerosis,Thrombosis, andVascular Biology, vol. 32, no. 1, pp. 74-81, 2012.
7. J. L. Johnson, G. B. Sala-Newby, Y. Ismail, C. M. Aguilera, and A. C. Newby, "Low tissue inhibitor of metalloproteinases 3 and highmatrixmetalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 9, pp. 1647-1653, 2008.
8. F. O. Martinez, L. Helming, and S. Gordon, "Alternative activation of macrophages: an immunologic functional perspective," Annual Review of Immunology, vol. 27, pp. 451-483, 2009.
9. D. M. Mosser and J. P. Edwards, "Exploring the full spectrum of macrophage activation," Nature Reviews Immunology, vol. 8, no. 12, pp. 958-969, 2008.
10. C. Monaco, S. M. Gregan, T. J. Navin, B. M. J. Foxwell, A. H. Davies, and M. Feldmann, "Toll-like receptor-2 mediates inflammation and matrix degradation in human atherosclerosis," Circulation, vol. 120, no. 24, pp. 2462-2469, 2009.
11. A. C. Newby, S. J. George, Y. Ismail, J. L. Johnson, G. B. Sala-Newby, and A. C. Thomas, "Vulnerable atherosclerotic plaque metalloproteinases and foam cell phenotypes," Thrombosis and Haemostasis, vol. 101, no. 6, pp. 1006-1011, 2009.
12. M. A. Bouhlel, B. Derudas, E. Rigamonti et al., "PPAR activation primes humanmonocytes into alternativem2macrophages with anti-inflammatory properties," Cell Metabolism, vol. 6, no. 2, pp. 137-143, 2007.
13. G. Chinetti-Gbaguidi, M. Baron, M. A. Bouhlel et al., "Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPAR and LXR pathways," Circulation Research, vol. 108, no. 8, pp. 985-995, 2011.
14. J. L. Stöger,M. J. J. Gijbels, S. van der Velden et al., "Distribution of macrophage polarization markers in human atherosclerosis," Atherosclerosis, vol. 225, no. 2, pp. 461-468, 2012.
15. A. V. Finn, O. Saeed, and R. Virmani, "Macrophage subsets in human atherosclerosis," Circulation Research, vol. 110, article e64, 2012.
16. A. Kadl, A. K. Meher, P. R. Sharma et al., "Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2," Circulation Research, vol. 107, no. 6, pp. 737-746, 2010.
17. J. J. Boyle, H. A. Harrington, E. Piper et al., "Coronary intraplaque hemorrhage evokes a novel atheroprotective macrophage phenotype," The American Journal of Pathology, vol. 174, no. 3, pp. 1097-1108, 2009.
18. J. J. Boyle, M. Johns, T. Kampfer et al., "Activating transcription factor 1 directs Mhem atheroprotective macrophages through coordinated iron handling and foam cell protection," Circulation Research, vol. 110, no. 1, pp. 20-33, 2012.
19. A. V. Finn, M. Nakano, R. Polavarapu et al., "Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques," Journal of the American College of Cardiology, vol. 59, no. 2, pp. 166-177, 2012.
20. B. A. N. Verhoeven, E. Velema, A. H. Schoneveld et al., "Athero-express: differential atherosclerotic plaque expression of mRNA and protein in relation to cardiovascular events and patient characteristics. Rationale and design," European Journal of Epidemiology, vol. 19, no. 12, pp. 1127-1133, 2004.
21. J.P.G. Sluijter,W. P. C. Pulskens,A.H. Schoneveldet al., "Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions-A study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms," Stroke, vol. 37, no. 1, pp. 235-239, 2006.
22. D. P. V. De Kleijn, F. L. Moll, W. E. Hellings et al., "Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events," Arteriosclerosis,Thrombosis, and Vascular Biology, vol. 30, no. 3, pp. 612-619, 2010.
23. W. E. Hellings, G. Pasterkamp, A. Vollebregt et al., "Intraobserver and interobserver variability and spatial differences in histologic examination of carotid endarterectomy specimens," Journal of Vascular Surgery, vol. 46, no. 6, pp. 1147-1154, 2007.
24. V. P. W. Scholtes, J. L. Johnson, N. Jenkins et al., "Carotid atherosclerotic plaque matrix metalloproteinase-12-positive macrophage subpopulation predicts adverse outcome after endarterectomy," Journal of the AmericanHeart Association, vol. 1, no. 6, Article ID e001040, 2012.
25. E. Monsalve, A. Ruiz-Garciá, V. Baladrón et al., "Notch1 upregulates LPS-induced macrophage activation by increasing NF-B activity," European Journal of Immunology, vol. 39, no. 9, pp. 2556-2570, 2009.
26. F. O.Martinez, S. Gordon, M. Locati, and A.Mantovani, "Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression," Journal of Immunology, vol. 177, no. 10, pp. 7303-7311, 2006.
27. D. Shiffman, T. Mikita, J. T. N. Tai et al., "Large scale gene expression analysis of cholesterol-loaded macrophages," The Journal of Biological Chemistry, vol. 275, no. 48, pp. 37324-37332, 2000.
28. S.-C.Sun,P.A.Ganchi,D.W. Ballard, andW.C.Greene, "NF-B controls expression of inhibitor IB: evidence for an inducible autoregulatory pathway," Science, vol. 259, no. 5103, pp. 1912-1915, 1993.
29. K. Di Gregoli, N. Jenkins, R. Salter, S. White, A. C. Newby, and J. L. Johnson, "Microrna-24 regulates macrophage behavior and retards atherosclerosis," Arteriosclerosis, Thrombosis, and Vascular Biology, 2014.
30. A.Mantovani, C. Garlanda, and M. Locati, "Macrophage diversity and polarization in atherosclerosis: a question of balance," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 10, pp. 1419-1423, 2009.
31. A. C. Thomas, G. B. Sala-Newby, Y. Ismail, J. L. Johnson, G. Pasterkamp, and A. C. Newby, "Genomics of foam cells and nonfoamy macrophages from rabbits identifies arginase-I as a differential regulator of nitric oxide production," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 3, pp. 571-577, 2007.
32. W. Peeters, W. E. Hellings, D. P. V. De Kleijn et al., "Carotid atherosclerotic plaques stabilize after stroke: insights into the natural process of atherosclerotic plaque stabilization," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 29, no. 1, pp. 128-133, 2009.
33. G. Chinetti-Gbaguidi and B. Staels, "Macrophage polarization in metabolic disorders: functions and regulation," Current Opinion in Lipidology, vol. 22, no. 5, pp. 365-372, 2011.
34. J. L. Johnson and A. C. Newby, "Macrophage heterogeneity in atherosclerotic plaques," Current Opinion in Lipidology, vol. 20, no. 5, pp. 370-378, 2009.
35. W.-C. Huang, G. B. Sala-Newby, A. Susana, J. L. Johnson, and A. C. Newby, "Classical macrophage activation up-regulates several matrix metalloproteinases through mitogen activated protein kinases and nuclear factor-B," PLoS ONE, vol. 7, no. 8, Article ID e42507, 2012.
36. B. Reel, G. B. Sala-Newby, W. Huang, and A. C. Newby, "Diverse patterns of cyclooxygenase-independent metalloproteinase gene regulation in human monocytes," British Journal of Pharmacology, vol. 163, no. 8, pp. 1679-1690, 2011.
37. J. SpannNathanael,X.Garmire Lana,G.McDonald Jeffrey et al., "Regulated accumulation of desmosterol integrates macrophage lipidmetabolismand inflammatory responses," Cell, vol. 151, pp. 138-152, 2012.
38. R. P. Fabunmi, G. K. Sukhova, S. Sugiyama, and P. Libby, "Expression of tissue inhibitor of metalloproteinases-3 in human atheroma and regulation in lesion-Associated cells: a potential protective mechanism in plaque stability," Circulation Research, vol. 83, no. 3, pp. 270-278, 1998.
39. M. Wick, R. Haronen, D. Mumberg et al., "Structure of the human TIMP-3 gene and its cell cycle-regulated promoter," Biochemical Journal, vol. 311, no. 2, pp. 549-554, 1995.
40. G. A. R. Doyle, U. K. Saarialho-Kere, andW. C. Parks, "Distinct mechanisms regulate TIMP-1 expression at different stages of phorbol ester-mediated differentiation of U937 cells," Biochemistry, vol. 36, no. 9, pp. 2492-2500, 1997.